Patients with hypersensitivity to the active substance(s), Patients undergoing haemodialysis, Patients with severe hepatic impairment, Patients with severe renal impairment who are also treated with a strong cytochrome P450 (CYP) 3A4 inhibitor, e.g., ketoconazole, Patients with moderate hepatic impairment who are also treated with a strong CYP3A4 inhibitor, e.g., ketoconazole, Patients with severe gastrointestinal conditions (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma and patients at risk for these conditions, Patients with a history of orthostatic hypotension.